Investment Rating - The investment rating for the company is "Buy" [1][4] Core Views - The company reported a revenue of 2.453 billion yuan in 2025, a year-on-year decrease of 18.94%, and a net profit attributable to shareholders of 1.291 billion yuan, down 34.05% year-on-year [1][2] - The decline in revenue is attributed to weak end-consumer demand in the medical beauty sector and intensified industry competition [2] - The company is actively expanding its product pipeline and pursuing internationalization, with the acquisition of Korean REGEN and the introduction of new products expected to contribute to future revenue growth [4] Financial Summary - In 2025, the company's gross margin was 92.70%, a decrease of 1.94 percentage points year-on-year, while the net profit margin was 52.64%, down 12.06 percentage points year-on-year [3] - The company’s operating expenses increased significantly due to the decline in revenue, with the expense ratio rising to 38.18%, an increase of 15.97 percentage points year-on-year [2] - The company plans to achieve revenues of 2.679 billion yuan, 3.032 billion yuan, and 3.302 billion yuan for 2026, 2027, and 2028, respectively, with net profits projected at 1.587 billion yuan, 1.797 billion yuan, and 1.984 billion yuan for the same years [4][6]

Investment Rating - The report maintains an "Outperform" rating for the company [2]. Core Insights - The company's performance in 2025 was impacted by a challenging consumption environment, resulting in a revenue decline of 18.9% to RMB 2.45 billion and a net profit decrease of 34.1% to RMB 1.29 billion [5][15]. - The acquisition of REGEN Biotech has positioned the company for future growth, with new products like AestheFill and PowerFill expected to contribute to revenue [7][19]. - The company is entering a new growth phase with the approval of Type A botulinum toxin, which is anticipated to enhance its product offerings [19]. Financial Performance Summary - Revenue for 2025 was RMB 2,453 million, down 18.9% from the previous year, with a net profit of RMB 1,291 million, reflecting a 34.1% decline [5][15]. - Quarterly revenue for 2025 showed slight recovery in Q4, with a 3.9% increase from Q3, although it was still down 9.6% year-on-year [5][16]. - The gross profit margin for 2025 was 92.7%, a decrease of 1.9 percentage points compared to the previous year [5][15]. Product Performance Summary - Revenue from solution-type products was RMB 1.26 billion, down 27.5%, while gel-type products generated RMB 890 million, down 26.8% [6][17]. - The newly acquired freeze-dried powder products generated RMB 210 million, indicating a new growth driver for the company [6][17]. - Other revenue, including cosmetics, increased by 36.7% to RMB 90 million, showcasing some resilience in the product mix [6][17]. Expense Analysis - The company's expense ratios increased significantly, with sales expense ratio at 15.8% (+6.7 percentage points), administrative expense ratio at 7.4% (+3.3 percentage points), and R&D expense ratio at 14.7% (+4.7 percentage points) [6][18]. - The increase in expenses is attributed to the dilution effect from declining revenue, costs associated with the REGEN acquisition, and ongoing R&D investments [6][18]. Earnings Forecast and Valuation - Revenue is expected to grow to RMB 2.70 billion in 2026 and RMB 2.92 billion in 2027, representing year-on-year growth of 10.1% and 8.2%, respectively [9][20]. - Net profit is projected to reach RMB 1.39 billion in 2026 and RMB 1.47 billion in 2027, with growth rates of 7.9% and 5.5% [9][20]. - The target price for the stock is set at RMB 160.6, based on a P/E ratio of 35x for 2026, reflecting a downgrade from previous estimates [9][20].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [2][4]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance than the market, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, underperforming the Shenwan A Index by 0.7 percentage points [4][5]. - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical for assessing market trends and performance [4][9]. - Notable company performances include: - Aimei Ke reported a revenue of 2.453 billion yuan for 2025, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [10]. - Juzi Biotechnology's revenue was 5.519 billion yuan, a slight decrease of 0.4%, with a net profit of 1.915 billion yuan, down 7.2% [10] [11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector is currently underperforming the market, with specific indices showing declines [4][5]. - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4% [4]. Company Highlights - Aimei Ke's Q4 2025 revenue was 588 million yuan, down 9.61% year-on-year, with a net profit of 198 million yuan, down 46.85% [10]. - Juzi Biotechnology's effective skincare products generated 4.337 billion yuan in revenue, a 0.8% increase, while medical dressings saw a 4.8% decline [11]. Market Trends - The report highlights the importance of upcoming earnings disclosures from major companies, which are expected to provide insights into market recovery and performance [4][9]. - The overall retail sales of cosmetics in January-February 2026 grew by 4.5%, indicating a relative resilience in the beauty sector compared to the overall retail market [14]. E-commerce and Brand Performance - The report provides data on e-commerce performance, noting that domestic brands are gaining market share, with significant growth in GMV for brands like Shangmei [13]. - The report emphasizes the competitive landscape, with domestic brands increasingly challenging international players in market share [21][23].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2] Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, which is 0.7 percentage points worse than the Shenwan A Index [4][5] - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical to monitor [4][10] - The report highlights the performance of major companies, noting that Aimeike's revenue for 2025 is projected at 2.453 billion yuan, a year-on-year decrease of 18.94% [11] Summary by Sections Industry Performance - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4%, indicating varied performance within the sector [4][5] - The report notes that the beauty care sector is entering earnings season, with several companies set to announce their financial results [10] Company Highlights - Aimeike's 2025 performance shows a revenue of 2.453 billion yuan, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [11] - Juzi Biotechnology reported a slight revenue decline of 0.4% to 5.519 billion yuan, with a net profit decrease of 7.2% [11] - The report emphasizes the importance of product matrix improvement and collaboration for growth in Aimeike's future performance [12] Market Trends - The report indicates that the retail sales of cosmetics in China grew by 4.5% year-on-year in the first two months of 2026, outperforming overall retail growth [16] - The report also notes that the domestic market is seeing a shift towards local brands, with significant growth in market share for domestic products [23] Industry Dynamics - The report discusses the strategic partnership between L'Oréal and NVIDIA to enhance AI research in beauty products, reflecting a trend towards technological integration in the industry [20] - The competitive landscape is evolving, with domestic brands gaining ground against international players, particularly in the skincare segment [23]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation of stock performance that exceeds market performance by 10% to 20% over the next six months [11]. Core Views - The company experienced a revenue decline in the first half of 2025, achieving 1.299 billion yuan, a year-over-year decrease of 21.59%. The net profit attributable to shareholders fell by 29.57% to 789 million yuan [4]. - The report highlights that the company is entering a low base period in the second half of the year, which may facilitate a return to growth [7]. - The company has a diverse product matrix, with several products in the registration phase, which could contribute to future revenue growth [8]. Summary by Sections Company Overview - The company operates in the retail industry with a total market capitalization of 55.6 billion yuan and a total share capital of 303 million shares [1]. Financial Performance - The company reported a gross margin of 93.44% and a net margin of 60.9% in the first half of 2025, with a basic EPS of 2.62 yuan [4][7]. - Revenue for 2023 is projected at 2.869 billion yuan, with a year-over-year growth of 48%, followed by a slight increase to 3.026 billion yuan in 2024 [6]. Future Projections - The report projects revenues of 1.781 billion yuan, 2.142 billion yuan, and 2.503 billion yuan for 2025, 2026, and 2027 respectively, reflecting a downward adjustment from previous estimates [8]. - The company is expected to maintain a robust product offering, which may enhance consumer solutions and drive growth in the upcoming periods [8].

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 公司发布2025年一季报，1Q2025营业收入为6.6亿元，同比下滑17.9%，归母净利润为4.4亿元，同比下滑 15.9%。 点评： 高基数+产品结构分化，一季度业绩有所下滑 我们认为，公司一季度收入同比下滑主要原因系：第一，去年同期基数较高；第二，产品销售结构性分 化，溶液类产品整体出货价格走低。 产品结构性分化，一季度毛利率略有下滑 1Q2025，公司毛利率为93.9%，同比-0.7pcts；归母净利率为66.9%，同比+1.6pcts。我们认为，公司一季 度毛利率同比微降也是受产品出货结构的影响。 1Q2025公司期间费用率同比+4.1pcts至21.9%。分项目看，销售/管理/研发/财务费用率分别为 9.9% ...

Core Insights - The company achieved a revenue of CNY 3.03 billion in 2024, representing a growth of 5.5%, and a net profit of CNY 1.96 billion, up by 5.3% [1] - The company maintained stable profitability with a gross margin of 94.6% and a net margin of 64.7% for the year [1] - In Q4 2024, the company reported a revenue of CNY 650 million, a decrease of 7.0%, and a net profit of CNY 370 million, down by 15.5% [1] Revenue and Profit Analysis - Revenue from solution products was CNY 1.74 billion, growing by 4.4% - Revenue from gel products reached CNY 1.22 billion, increasing by 5.0% - Revenue from facial implant lines was approximately CNY 6.804 million, up by 15.0% - Other revenues, including cosmetics, amounted to CNY 59.192 million, a significant increase of 68.5% [1] R&D and Acquisition Strategy - The company increased its R&D expense ratio to 10.0%, up by 1.3 percentage points, indicating a focus on product pipeline development [2] - The company announced plans to acquire 85% of South Korean REGEN for USD 19 million, which is expected to significantly contribute to revenue and profit by 2026 [2] - The acquisition includes two listed products, AestheFill and PowerFill, which are anticipated to enhance the company's market position [2] Earnings Forecast and Valuation - Revenue projections for 2025 and 2026 are CNY 3.30 billion and CNY 3.60 billion, reflecting year-on-year growth of 9.2% and 9.1% respectively [3] - Net profit forecasts for the same years are CNY 2.02 billion and CNY 2.18 billion, with growth rates of 3.1% and 7.7% [3] - The target price for the company is set at CNY 299.47 per share, based on a price-to-earnings ratio of 45x for 2025 and 42x for 2026 [3]

Investment Rating - The report maintains an "Outperform" rating for the company [1][2][7] Core Views - The company achieved steady growth in 2024, with revenue of Rmb 3.03 billion (+5.5%) and net profit of Rmb 1.96 billion (+5.3%), maintaining a gross profit margin of 94.6% [3][11] - The company is focusing on overseas mergers and acquisitions, particularly the proposed acquisition of REGEN in South Korea, which is expected to significantly contribute to revenue and profits in 2026 [4][16] Financial Performance - Revenue and profit growth for 2024: Revenue of Rmb 3,026 million, net profit of Rmb 1,958 million, with a gross profit margin of 94.6% [3][11] - Q4 2024 performance showed a revenue decline of 7.0% to Rmb 650 million and a net profit decline of 15.5% to Rmb 370 million [12] - Revenue by product category: Solution-based products Rmb 1.74 billion (+4.4%), Gel-based products Rmb 1.22 billion (+5.0%), Facial implant threads Rmb 6.804 million (+15.0%), Other revenue Rmb 59.192 million (+68.5%) [13][14] Research and Development - Increased R&D investment with a ratio of 10.0% in 2024, focusing on new product pipelines and clinical trials [4][15] - The company has received clinical trial approvals for several new products, indicating a commitment to innovation [15] Acquisition Strategy - The proposed acquisition of REGEN for US$190 million is expected to enhance the company's product offerings and production capacity, with the second factory in South Korea expected to start production in Q2 2025 [4][16] - The target company reported revenue of Rmb 72.23 million and net profit of Rmb 29.5 million from January to September 2024 [16] Earnings Forecast and Valuation - Revenue projections for 2025 and 2026 are Rmb 3.30 billion and Rmb 3.60 billion, respectively, with year-on-year growth of 9.2% and 9.1% [5][17] - The target price is set at Rmb 299.47 per share, corresponding to a P/E ratio of 45x for 2025 and 42x for 2026 [7][17]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [2][8][14]. Core Insights - The company reported a revenue of 3.03 billion yuan for 2024, reflecting a year-on-year growth of 5.4%, with a net profit of 1.96 billion yuan, also up by 5.3% [4][6]. - The sales of solution products have shown rapid growth, with revenues of 1.74 billion yuan for solution products and 1.22 billion yuan for gel products, marking year-on-year increases of 4.4% and 5.0% respectively [5]. - The company is expanding its product portfolio and exploring overseas markets, including a planned acquisition of REGEN Biotech, which is expected to enhance its competitiveness in the regenerative field [7]. Summary by Sections Company Overview - The latest closing price is 187.61 yuan, with a total market capitalization of 56.8 billion yuan and a circulating market value of 39.1 billion yuan [3]. - The company has a low debt ratio of 5.4% and a price-to-earnings ratio of 21.82 [3]. Financial Performance - The gross margin for 2024 is projected to be 94.6%, with a slight decline of 0.5 percentage points year-on-year, while the net profit margin remains high at 64.7% [6]. - The company plans to distribute a cash dividend of 38 yuan per 10 shares [4]. Future Outlook - The company anticipates a net profit of 2.13 billion yuan in 2025, with projected growth rates of 7.95% for the following years [10][11]. - The report highlights the potential for growth through product diversification and international expansion, despite short-term pressures from market conditions [7].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 202.76 CNY [3][6]. Core Views - The company faces short-term challenges but aims for long-term growth through both internal and external strategies [1][6]. - The profit forecast has been adjusted, with expected net profits for 2025-2027 at 2.166 billion, 2.452 billion, and 2.817 billion CNY respectively [2][6]. - The company is expanding its product pipeline and has made a strategic acquisition to enhance its international presence [5][6]. Financial Summary - **Revenue Forecast**: Expected revenues for 2025-2027 are 3.411 billion, 3.952 billion, and 4.639 billion CNY, with growth rates of 12.8%, 15.8%, and 17.4% respectively [2][11]. - **Profitability Metrics**: The gross margin is projected to decline from 95.1% in 2023 to 88.7% in 2027, while the net profit margin is expected to decrease from 64.8% to 60.7% over the same period [2][11]. - **Earnings Per Share (EPS)**: EPS is forecasted to increase from 6.14 CNY in 2023 to 9.31 CNY in 2027 [2][11]. - **Valuation Ratios**: The price-to-earnings (P/E) ratio is expected to decrease from 31.6 in 2023 to 20.8 in 2027, indicating a potential increase in value [2][11].